Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

计划入组 2 人 · 首次发布于 2021 年 6 月 2 日

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

计划入组 30 人 · 首次发布于 2024 年 10 月 1 日

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

计划入组 33 人 · 首次发布于 2021 年 10 月 8 日

pan-BET inhibitor-tumor-targeting ligand conjugate (prostate cancer)

Molibresib

C₂₂H₂₂ClN₅O₂

BET bromodomain inhibitors (inflammation)

Corvus Pharmaceuticals

United States

Kura Oncology

United States

Odyssey Therapeutics

BRD2 Emerges as Key Driver of BET Inhibitor Resistance Across Multiple Cancers

Chinese BET Inhibitor NHWD-870 Receives Breakthrough Therapy Designation for Rare NUT Carcinoma

Jacobio Pharma Receives IND Acceptance for BET Inhibitor JAB-8263 in Autoimmune Diseases